IVDR And Brexit Outlook For IVD Firms: EU Themes To The Fore At Asian Medtech Associations Reg Networking
Executive Summary
This month’s Asian Medtech Associations Regulatory Networking discussions is split into two parts, the first being a guest presentation on EU themes, specifically a UK Brexit outlook and an update on the progress of the EU IVDR, which comes into full effect on 26 May 2022. Both have potentially far-reaching effects for Asian and other global medtech markets. Part two will feature AHWP and Asean updates, as usual. This editorial feature is hosted by Medtech Insight, along with the Asia Regulatory and Quality Consultancy (ARQon) and the Asia Regulatory Professionals Association (ARPA).
You may also be interested in...
Asia Reg News: AHWP Catch-Up, Korea, Malaysia, Indonesia and Vietnam Updates
Part 1 of this month’s Asian Medtech Associations Regulatory Networking discussions features Asean medtech market developments and Asian Harmonization Working Party news. Part 2 was a guest presentation on the current Brexit and EU IVDR outlook. This feature is hosted by Medtech Insight, the Asia Regulatory and Quality Consultancy (ARQon) and the Asia Regulatory Professionals Association (ARPA).
QUOTED. 11 June 2019. Bassil Akra.
TÜV SÜD Product Service's Bassil Akra is concerned that there won't be enough notified bodies to audit to the new EU Medical Device and In Vitro Diagnostic Regulations when they come into force in 2020 and 2022, respectively. Check out his comments here.
EU Officially Designates Second Notified Body Under The MDR: TÜV SÜD Enters Center Stage
TÜV SÜD, headquartered in Germany, is the second notified body to be officially designated under the EU MDR. Is this good news going to significantly lessen medtech industry’s concerns over delays in accessing the new, tougher regulatory system for medical technology, with time running seriously short?